You can add Maine to the growing list of states that have passed a law seeking more transparency about prescription drug pricing.
However, unlike a few states that quickly required drug makers to provide cost and pricing information about their medicines – California, Vermont, Nevada, and Oregon — Maine is taking a two-step approach.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
This line struck me – “passing legislation to lower drug costs should be a “top priority” for President Trump, who is expected to deliver a speech about the issue.”
I thought the President’s objection to the last administration was ‘all talk and no action’ – the tradition continues, it would seem. (And wasn’t said speech due last week?)
please send me the information